By Dan Schell, Chief Editor, Clinical Leader
I’m not sure what prompted the response from Rachel Haurwitz. It was, after all, a simple “thank you” that I had sent her via LinkedIn back in November 2017 for contributing some comments to our 2018 outlook issue. As CEO and president of one of the hottest CRISPR-based companies at the time, Caribou Biosciences, Haurwitz, I was sure, was inundated with LinkedIn connection requests and every other form of communication that clogs a top executive’s inbox. So when I almost immediately got a response, I was shocked.